SCHEMBL23723615

SCHEMBL23723615

Cc1cc2nc(CN(C)CC(=O)N(C)c3ccc(Cl)c(Cl)c3)[nH]c(=O)c2s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.41
CCNE1 P24864 2/20 0.41
CDK2 P24941 2/20 0.41
ROCK1 Q13464 2/20 0.41
DBF4 Q9UBU7 2/20 0.41
PDE5A O76074 1/20 0.38
PIM1 P11309 8/20 0.38
PIM2 Q9P1W9 7/20 0.38
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
LMNA P02545 2/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
PIM3 Q86V86 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30132032 1.00 CDC7 (0.41) CDC7CCNE1CDK2ROCK1DBF4
SCHEMBL23723556 0.85 ALPL (0.41) CDC7CCNE1CDK2ROCK1DBF4
SCHEMBL30132075 0.85 ALPL (0.41) CDC7CCNE1CDK2ROCK1DBF4
SCHEMBL30132028 0.84 PIM1 (0.43) CDC7CCNE1CDK2ROCK1DBF4
SCHEMBL23723612 0.84 PIM1 (0.43) CDC7CCNE1CDK2ROCK1DBF4
SCHEMBL23723517 0.82 PIM1 (0.37) PDE5APIM1PIM2KDM4EALDH1A1
SCHEMBL30120668 0.82 PIM1 (0.37) PDE5APIM1PIM2KDM4EALDH1A1
SCHEMBL30120714 0.82 KMT2A (0.42) KDM4EALDH1A1LMNAALPLALPI
SCHEMBL23723547 0.82 KMT2A (0.42) KDM4EALDH1A1LMNAALPLALPI
SCHEMBL26095189 0.82 GAA (0.43) KDM4EALDH1A1HTTLMNAALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
EP-4100015-A1 COMBINATION THERAPY FOR TREATING MPS1 Gain Therapeutics SA (CH) 2022-12-14 EP disclosed
CN-115397423-A Combination therapy for the treatment of MPS1 增益治疗股份有限公司 2022-11-25 CN disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 CDC7 4673/4885CCNE1 1144/4885CDK2 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.